United Therapeutics (UTHR)
(Real Time Quote from BATS)
$236.41 USD
+4.63 (2.00%)
Updated Apr 17, 2024 02:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 141 - 160 ( 583 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso/PH-ILD Setting Positive Tone in 2021 Ahead of Value- Driving Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
PRV Bought for $105M Creates Expedited Regulatory Review for Tyvaso DPI
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Treprostinil/IPF: FDA Grants ODD; On-Track to Start Ph3 TETON Study in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Evolving PAH and Lung Disease Platform Presents Several Paths Yet to Be Distinguished
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Strong Q3, Plenty of Cash and Positive 2021 Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso® Safety Data at CHEST 2020 Adds Momentum to Catalyst-Rich 2021 (Erratum)
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
PTAB Decision Paves Way for TreT First-to-Market; Pivotal Data/Filing in Q1:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso®/PH-ILD sNDA Acceptance Setting Up Expansion Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Potential Drivers for Platform Growth Abound, But Our Focus Remains on Execution; Reit Neutral and $125 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A